JAV: DrBio45, your posts continue to present 1/10 of the story: You specifically stated in 2 posts that 1. JAV's pps isn't going anywhere due to UK approval, and 2. they won't make any money in the EU with Dyloject. You seem to conveniently omit the following:
1. UK approval is but 30% of total expected EU revenue.
2. Dyloject EU is but 25% of Dyloject total Worldwide
3. Dyloject is <40% of total JAV revs by 2010; assuming Ketamine gets approval in US.
4. No analyst (nor the Company) has ascribed any future revs to Ketamine ex-USA or any revs for Rylomine. "Yet."
May I assume that all companies seek EU approval to lose money on their respective products? Let's sell drugs at at loss in EU just to be nice to our Forefathers?
But, thanks for your "complete" JAV assessments...
"Illegitimacy is something we should talk about in terms of not having it."
- Dan Quayle
